A Phase 1, Open-Label, Non-randomized, Single-Center Study to Assess Distribution, Metabolism and Excretion After [14C]-Labelled Intravenous Administration of AZD9742 as a 2-hour Infusion to Healthy Male Volunteers.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs AZD 9742 (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 24 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 21 Jan 2011 New trial record